β3 agonists

β3 agonists has been studied in 2 papers since 2022: 1 observational study in people, 1 review; 1 in the past year. The newest story, Nov 6, 2026: “Bladder drugs presumed safer not linked to lower dementia risk”.

Intervention

2 papers study it1 findingUpdated Nov 6, 2026

1 new paper in 30 daysSee all 2 papers on β3 agonists

Humans1

What is β3 agonists linked with?

Studies link β3 agonists with 1 measure, most often mortality (1 study).

Mortality

downin humans1−20%

1 study

β3 agonists lower the risk of mortality in humans (-20%).
“β3 agonist users had a 20% lower risk of mortality compared to OAB anticholinergic users.”
Review
The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists
European urology focusAug 17, 2022

Latest

1 paper in 12 months

JAMA Network OpenNov 6

Bladder drugs presumed safer not linked to lower dementia risk

Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.

Cohort · 830,393 peopleIncident dementia

Paper

European Urology FocusAug 21

The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists

ReviewOveractive bladder